盐酸替罗非班在冠心病临床治疗中的应用研究  

Application of Tirofiban Hydrochloride in Clinical Treatment of Coronary Heart Disease

作　　者：高颖[1] 肖冬[1] 王辉[1] 

机构地区：[1]济南医院内科,山东济南250000

出　　处：《系统医学》2017年第13期56-58,共3页Systems Medicine

摘　　要：目的探讨对冠心病患者行盐酸替罗非班治疗的临床效果。方法将2015年11月—2016年11月该院收治的96例冠心病患者作为研究对象,随机分为常规组和研究组,各46例。常规组行低分子肝素治疗,研究组行盐酸替罗非班治疗,观察并比较两组不良反应发生率以及治疗有效率。结果研究组治疗有效率45例(97.83%)显著高于常规组36例(78.26%),研究组发生不良反应几率2例(4.35%)显著低于常规组14例(30.43%),差异有统计学意义(P<0.05)。结论对冠心病患者行盐酸替罗非班治疗,不仅能够降低患者发生不良反应的几率,同时,还能够提高整体治疗效果,利用患者的病情恢复。Objective This pap er tries to investigate the clinical effect of tirofiban hydrochloride in patients with coro-nary heart disease. Methods 96 patients with coronary heart disease from November 2015 to November 2016 in this hospital were selected and randomly divided into the conventional group and the research group with 46 cases in each group. The conventional group adopted low molecular weight heparin treatment, the research group was treated with tirofiban hydrochloride, and then the incidence of adverse reactions and treatment efficiency in both groups were ob-served and compared. Results In the research group, the curative efficiency of the research group was 97.83% with 45 cases, significantly higher than those in the conventional group of 78.26% with 36 cases. The risk of adverse reactions in the research group was 4.35% with 2 cases, significantly lower than that in the conventional group of 30.43% with 14 cases, the difference was statist ical ly significant （P〈0.05）. Conclusion The tirofiban in patients with coronary heart disease can not only reduce the risk of adverse reactions, but also can improve the overall treatment efficiency, and benefit patients＇ recovery.

关 键 词：盐酸替罗非班 冠心病患者 不良反应 治疗效果 

分 类 号：R541.4[医药卫生—心血管疾病]